Acusphere, Inc. June 5 announced that it has entered into an agreement to license on a non-exclusive basis various ultrasound-related intellectual property from GE Healthcare, a division of General Electric Company. The Agreement provides Acusphere with use of GE's ultrasound contrast agent patents in combination with Acusphere's lead product candidate AI-700 in the field of ultrasound contrast agents, as well as any patents that GE acquires in the field within 12 months of the Agreement. The term of this Agreement extends until expiration of the last of the patents licensed under the Agreement. Acusphere is developing AI-700, currently in Phase 3 clinical trials, as an ultrasound contrast agent to support the assessment of myocardial perfusion, or blood flow within the heart muscle, an indication for which no contrast agent is currently approved.
Genetic Engineering News
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
CoreLink’s 3D Anterior Lumbar Approved by FDA
The implant allows for better imaging by minimizing material density.
Endo Resumes Lawsuit Against FDA Over Bulk Drug Compounding Decree
The company claimed the agency’s handling of bulk compounding laws violates the 2013 Drug Quality and Security Act, treating the laws as non-binding guidance rather than a legal mandate.
FDAnews Device Daily Bulletin
ACUSPHERE LICENSES ULTRASOUND CONTRAST-RELATED TECHNOLOGY RIGHTS FROM GE HEALTHCARE
June 7, 2006